Introduction
The incidence of chronic ITP is about 10 in every 100,000 and is most often in adults with female predominance 1, 2, 3 . Corticosteroid is the mainstay of treatment but unfortunately thrombocytopenia usually recur when treatment is discontinued.
Splenectomy is the definitive treatment with permanent response in more than 70% of patients 4, 5 . Immunosuppressive drugs including vinca alkaloid will often produce response where above treatment fail (Refractory) or when they are impractical or contraindicated. With IV Vincristine, improvement occurs in more than half of the patient refractory to prednisolone or splenectomy 6 . Most subsequent studies also found relatively high rates but the majority of response were transient 3, 7 . Danazol 12,13 is a synthetic steroid derived from ethisterone. It is an attenuated androgen, has been effective in increasing platelet counts in patient with ITP. The mechanism of action is induced reduction of of Fc receptors on phagocytic cells. 
Material and Methods

Results
Most of the patients 60 % were female and 40 % were male, 56 % patient were between 21 to 40 yrs , 32 % were between 15 to 20 yrs, 4 % were more than 50 years. All patients presented with purpura and easy bruise , 80 % have gum bleeding & epistaxis, subconjunctival hemorrhage ( 30 %),
Full blood counts were normal except thrombocytopenia, prolong bleeding time. Antinuclear factor was absent and LE cell test was negative. Antiplatelet antibodies was not detected because there is lack of facility.Out of 50 patients 7 (14.5%) were in complete remission and 35 (72.9%) were in partial remission after danazol. 
Discussion
This study provides to see the outcome of treatment with danazol of patients with chronic ITP refractory to prednisolone, azathioprine, vincristine or cyclophosphamide 11 . Age of study population were between 15 -55 years. 56% of the patient were belong to 21-40 yrs & 32% were between 15-20 yrs. 60% were female and 40% were male. Clinical presentation were purpura and brusie (100%), gum bleeding & epistaxis (80%), menorrhagia (50% of female patients), subconjunctival haemorrhage (30%), hematuria (20%). Two female patient had anemia with hemoglobin 6.4 gm/dl. One patient reported with visual impairment. In all patients of study platelet count had 30×10 9 / L or less with large platelets in peripheral blood and bone marrow of all patients shown increased number of young megakaryocytes 10 . Antinuclear antibody (ANA) and LE cell (lupus erythematosis) test were negative in all patients. More than half of the refractory ITP patients improved by danazol 8. Responses generally occur within 5 -10 days much sooner than with azathioprine and cyclophosphamide 11 . Out of 50 patients 2 discontinued the therapy after 1 st week and they were excluded from this study.
After starting of danazol on day 7, response rate was 79.2 % (platelet count raised in 42 patients out of 48). On 4 th week follow up, 25% (12 patients) achieved (CR) complete remission (platelet count ≥ 1,50,000/cmm), 63.5% (30 patients) achieved (PR) partial remission (platelet count ≥ 50,000 -< 1,50,000/cmm) and 6 had no response at all. On 8 th week, 7 patients remained in CR (37.5%), 5 in relapsed and remained in partial remission. 37.5% (7) patients remained in CR, 5 patient relapsed and remained in partial remission at 12 th week of treatment.
Conclusion
Chronic ITP refractory to prednisolone & other drugs remains a serious problem all over the world. Splenectomy is the treatment of choice but our patient do not easily agreed to have splenectomy. Though danazol has limited benefit in chronic ITP but its prompt thrombocytosis effect, less toxicities and no carcinogenic effect make it more popular. Thus we can use danazol in chronic ITP patient refractory to prednisolone or others immunosuppressive agents.
